Literature DB >> 9354666

A recombinant human scFv anti-Rh(D) antibody with multiple valences using a C-terminal fragment of C4-binding protein.

M T Libyh1, D Goossens, S Oudin, N Gupta, X Dervillez, G Juszczak, P Cornillet, F Bougy, B Reveil, F Philbert, T Tabary, D Klatzmann, P Rouger, J H Cohen.   

Abstract

Monomeric recombinant molecules prove generally unsatisfactory for in vivo use. Most biological systems are indeed multivalent either structurally, associating different chains, or functionally, when cross-linked by their ligands. Mimicking natural molecules for immune intervention implies the need for multimerizing systems to create multivalent molecules capable of interfering with physiological processing. A multivalent anti-Rh(D) recombinant protein has been designed by reconstructing the antibody binding site of a human monoclonal anti-Rh(D) antibody as a single chain Fv mini antibody, then multimerizing it by inserting at its C-terminal end the C-terminal part of the C4 binding protein (C4bp) alpha chain, which is responsible for the octamer multimerization of that molecule. This soluble multivalent recombinant molecule was functional, bound red blood cells (RBCs), agglutinated them, and did not activate complement. This demonstration model opens the way for future in vivo use of multivalent molecules associating antibody valences and other functional molecules for cell targeting, imaging, or removal of cells such as Rh(D)-positive RBCs for preventing Rh alloimmunization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354666

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

Review 2.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

3.  An Ultrasensitive Bioluminescent Enzyme Immunoassay Based on Nanobody/Nanoluciferase Heptamer Fusion for the Detection of Tetrabromobisphenol A in Sediment.

Authors:  Zhenfeng Li; Yi Wang; Natalia Vasylieva; Debin Wan; Zihan Yin; Jiexian Dong; Bruce D Hammock
Journal:  Anal Chem       Date:  2020-07-07       Impact factor: 6.986

4.  Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo.

Authors:  D Christiansen; P Devaux; B Réveil; A Evlashev; B Horvat; J Lamy; C Rabourdin-Combe; J H Cohen; D Gerlier
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  The Hidden Side of Complement Regulator C4BP: Dissection and Evaluation of Its Immunomodulatory Activity.

Authors:  Inmaculada Serrano; Ana Luque; Francesca Mitjavila; Anna M Blom; Santiago Rodríguez de Córdoba; M Cristina Vega; Joan Torras; Josep M Aran
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

6.  The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria.

Authors:  Solabomi A Ogun; Laurence Dumon-Seignovert; Jean-Baptiste Marchand; Anthony A Holder; Fergal Hill
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

Review 7.  Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.

Authors:  Carlos H Villa; Aaron C Anselmo; Samir Mitragotri; Vladimir Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2016-03-03       Impact factor: 15.470

8.  Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates.

Authors:  Alexandra J Spencer; Fergal Hill; Jared D Honeycutt; Matthew G Cottingham; Migena Bregu; Christine S Rollier; Julie Furze; Simon J Draper; Karen C Søgaard; Sarah C Gilbert; David H Wyllie; Adrian V S Hill
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

9.  Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity.

Authors:  Marion Pepin; Soraya Mezouar; Julie Pegon; Vincent Muczynski; Frédéric Adam; Elsa P Bianchini; Amine Bazaa; Valerie Proulle; Alain Rupin; Jerome Paysant; Laurence Panicot-Dubois; Olivier D Christophe; Christophe Dubois; Peter J Lenting; Cécile V Denis
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

10.  T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.

Authors:  Emily K Forbes; Simone C de Cassan; David Llewellyn; Sumi Biswas; Anna L Goodman; Matthew G Cottingham; Carole A Long; Richard J Pleass; Adrian V S Hill; Fergal Hill; Simon J Draper
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.